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Abstract
Aim To assess whether incidence of maternal and neonatal outcomes for women with or without gestational diabetes
mellitus (GDM) have changed over time.
Methods Population-based cohort study in Sweden including all singleton pregnancies over the period 1998–2012.
GDM was diagnosed following Diabetic Pregnancy Study Group 1991 criteria. Poisson regression or negative binomial
regression was used to model yearly relative change in numbers of cases and incidence of the outcomes with 95%
confidence intervals (CI), and yearly absolute change in birthweight z-score.
Results The study included 1 455 667 pregnancies. The number of pregnancies increased over time and the overall
prevalence of GDM was 1%. For women with GDM there was a significantly decreasing trend in incidence per year for
large for gestational age (LGA) (0.986, 95% CI 0.975 to 0.996), birthweight z-score (0.012, 95% CI 0.017 to
0.007) and birth trauma (0.937, 95% CI 0.907 to 0.968). The trend for small for gestational age (SGA) among women
with GDM increased by an odds ratio per year (1.016, 95% CI 1.002 to 1.029). No significant interaction tests for
maternal characteristics were found. Trends in outcomes for women without diabetes were similar to those for women
with GDM.
Conclusions This study shows that there were improvements in pregnancy outcomes for women with GDM between
1998 and 2012, although the incidence of SGA increased. Improvements followed similar trends in the background
population. Inequalities in obstetric outcomes between women with GDM and those without have continued unchanged
over 15 years, suggesting that new management strategies are required to reduce this gap.
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Introduction
Hyperglycaemia in pregnancy is an increasing problem
worldwide. In Sweden, rates of type 1 and type 2 diabetes
mellitus in pregnancy, as well as gestational diabetes mellitus
(GDM) are increasing [1]. Women with GDM are at greater
risk for maternal and neonatal complications, and in 1989,
the St Vincent Declaration set the goal that the pregnancy
outcomes for women with diabetes should be comparable
with those for women without diabetes [2–4]. There are few
studies of trends in pregnancy outcomes for women with
GDM over time. There is one study by Feig et al. from
Canada, focusing on uncommon outcomes such as perinatal
mortality [5]. Another recent single-centre study from Den-
mark reported decreasing birthweight in offspring of women
with GDM [6]. During the past few decades there have been
improvements in the medical care of both pregnant women
with andwithout GDM. For example, the use of ultrasound as
a tool for evaluating fetal well-being and weight is now more
reliable, and the quality of the examination is better [7,8].
Maternal health care has focused to a greater extent on
improving weight gain and lifestyle, alongside a shift to more
visits in early pregnancy [9]. The criteria for GDM in Sweden
have remained largely unchanged over this period allowing an
evaluation of outcomes over time.
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The aim of this study was to assess whether incidence of
maternal and neonatal outcomes for women with GDM have
changed over the period 1998–2012 in Sweden. Because such
outcomes would be affected by wider population changes
and changes in care, we compared the trends for women with
GDM and women without GDM.
Methods
This is a population-based cohort study including all
singleton pregnancies resulting in a birth in Sweden over
the period 1998–2012. Women with pregestational diabetes
were excluded. Data were obtained from the Swedish
Medical Birth Register (MBR), which is maintained by the
National Board of Health and Welfare. The MBR contains
data on 98% of all pregnancies, including anthropometric
data and complications during pregnancy, delivery and the
neonatal period. Data were collected prospectively during
the pregnancy after obtaining oral consent from the pregnant
women. The MBR does not have information on laboratory
measures such as HbA1c. The registry has been validated and
the quality is regarded as high [10].
Screening and diagnoses of GDM
In Sweden during the study period, GDM screening was
performed by four to six random, repeated capillary blood
glucose measurements during pregnancy, in combination
with screening using traditional risk factors in 87% of
pregnancies. If the capillary plasma blood glucose was ≥ 9
mmol/l, an oral glucose tolerance test (OGTT) was per-
formed with fasting and 2-h glucose measurements. If
traditional risk factors were identified such as previous
pregnancy affected by GDM, previous birth of a large for
gestational age (LGA) or a macrosomic baby (> 4500 g),
BMI (kg/m2) > 30 or > 35 in early pregnancy and family
history of diabetes mellitus, an OGTT was performed in
gestational week 28–32. Criteria differed by region.
Accelerated growth or polyhydramnios was also an indica-
tion for OGTT in most centres. If a woman had a high
random glucose early in pregnancy and the subsequent
OGTT was normal, a repeat OGTT was undertaken at 28–
32 weeks’ gestation. In the southern region of Sweden,
screening was made by offering every woman a simplified
OGTT in pregnancy at week 28–32 with measurement of 2-h
value and no fasting value [11]. This region represented 13%
of the population.
The diagnosis of GDM was made by undertaking a 75-g
OGTT using capillary sampling: no region used venous
sampling for the OGTT at any time. The main diagnostic
criteria during 1998–2003 were fasting glucose ≥ 6.1 mmol/l
or a 2-h value ≥ 9 mmol/l using capillary whole blood [12].
In 2004, there was a shift to measuring glucose in capillary
plasma. The new ‘converted’ criteria for capillary plasma
were: fasting value ≥ 7 mmol/l and 2-h value ≥ 10 mmol/l.
In one region, which comprised ~ 20% of the population,
only overt diabetes (fasting capillary plasma glucose
≥ 7 mmol/l or a 2-h value ≥ 12.2 mmol/l) was diagnosed
during 1998–2010. After 2011, the region changed to the
main diagnostic criteria described above. Women diagnosed
with GDMwere treated according to local protocols: all with
dietary advice and insulin therapy if considered hypergly-
caemic (usually if several fasting values during a week were
> 6–6.5 mmol/l and/or post-meal values were > 8 mmol/l).
Definition of outcomes
Weight was registered at the first antenatal visit early in
pregnancy (gestational week 12–14) without shoes in light
clothes. Height was registered at recall. BMI was calculated
as weight (kg)/length (m)2. When adjusting for BMI, we used
the categories defined by the World Health Organization
(WHO): underweight (< 18.5 kg/m2), normal weight (18.5–
24.9 kg/m2), overweight (≥ 25.0–29.9 kg/m2), obese 1
(≥ 30.0–34.9 kg/m2) and obese 2 (≥ 35 kg/m2). Women with
extreme values for weight and height were excluded (weight
< 30 or > 200 kg, height < 100 or > 200 cm). Smoking was
defined as smoking at first antenatal visit. Women were
divided into two groups depending on country of birth,
Nordic (Sweden, Denmark, Norway, Finland, Iceland) and
non-Nordic. Pregnancy and neonatal outcomes were identi-
fied using codes in the International Statistical Classification
of Diseases and Related Health Problems 10th revision (ICD-
10). Chronic hypertensive disease was defined as blood
pressure (BP) ≥ 140/90 mmHg before gestational week 20,
ICD-code O10.0, O10.2, O10.4 or O10.9. GDM was
defined as ICD-code O24.4A or O24.4B. Pre-eclampsia
was defined as BP ≥ 140/90 mmHg and proteinuria
> 0.3 g 24 h1 l1, ICD-code O14, O14.0, O14.1A,
O14.1B, O14.1C, O14.1X, O14.2, O14.9 after gestational
week 20. Perinatal mortality was defined as stillbirth, ICD
code O36.4, or neonatal death within 7 days from birth. In
the study period before 2008, stillbirth included fetal death
What’s new?
• Women with gestational diabetes (GDM) have a higher
incidence of adverse maternal and perinatal outcomes
during pregnancy and labour.
• The trends for maternal and perinatal outcomes are
similar for women with GDM and women without
GDM.
• Among women with GDM and those without, birth
trauma has declined in parallel with reductions in
birthweight and rates of large for gestational age, and
increases in rates of small for gestational age.
• The differential in outcomes between women with
GDM and those without has persisted over 15 years.
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after 28 completed weeks of gestation. In 2008, the definition
changed to include fetal death after 22 completed weeks.
Premature birth was defined as birth before 37 completed
gestational weeks. Birth trauma included Erb’s palsy, spinal
cord injury, basal skull fracture, intracranial haemorrhage
and fracture of long bones, ICD-codes P14.0-3, P11.5, P11.9,
P13.0-1, P10.0-4, P10.8-9, P13.2-4 and P13.8-9 according to
the definition of Feig et al. [13]. LGA was defined as
birthweight over the 90th percentile within the data set,
excluding stillbirths, major malformation and multiple
pregnancies. Small for gestational age (SGA) was defined as
birthweight lower than the10th percentile within the data set
with the same exclusions as for LGA. The validity of these
SGA and LGA cut-offs was confirmed by comparison with an
older national data set derived from the MBR 1991–1997
[2]. The z-score for birthweight was calculated using
national, standardized growth references [14] from 1990 to
1999, not necessarily reflecting the current population.
Statistical analysis
For categorical variables, v2-test for trend was used to
analyse possible changes in maternal characteristics between
the periods; for continuous variables, one-way analysis of
variance (ANOVA) was used. Linear regression was used to
evaluate trend for z-score for birthweight over the years.
Yearly incidence during 1998 to 2012 of the outcomes: pre-
eclampsia, caesarean section, perinatal mortality, premature
birth, birth trauma, LGA and SGA was calculated by
dividing number of cases by the number of pregnancies in
the Swedish population. We used Poisson regression or
negative binomial regression to model the yearly relative
change in the number of cases and the incidence of the
outcomes with 95% confidence intervals (CI). For example,
an incidence change of 1.020 represents a 2.0% increase per
year and a change of 0.980 represents a 2.0% decrease per
year. The Poisson regression was evaluated by Pearson’s
goodness-of-fit test, and if the variation exceeded that of the
Poisson distribution, negative binomial regression was used
instead. The analyses were performed for the GDM popu-
lation in total and stratification with interaction tests were
performed on mother’s BMI, categorized as above, country
of birth (Nordic/non-Nordic), age (< 25, 25–34, ≥ 35 years),
smoking status and chronic hypertension. Because the
incidence of LGA indicated different trends over time, the
analyses were performed in two periods, 1998–2007 and
2008–2012, and the yearly relative changes were compared
between the periods using interaction tests. Analyses of SGA
and LGA were repeated after exclusion of women with
intercurrent disease during pregnancy to exclude potential
effects on fetal size. Incidence trends for women without
GDM were also reported. Intercurrent disease was defined as
ICD code O10.0, O10.2, O10.4, O10.9, O98.0-2, O98.4 A-
C, O98.4W-X, O98.7 and O99.0-8. A P-value of < 0.05 was
considered significant. All statistical analyses were conducted
using IBM SPSS version 22 (Armonk, NY, USA) or STATA
release 14 (Stata Corp, College Station, TX, USA).
Ethical approval
The study was approved by the Regional Ethical Committee
in Uppsala, Sweden (2009/187/1); date of approval 25
October 2017. The study followed the Declaration of
Helsinki.
Results
After exclusions, the study cohort included 1 455 667
women; 1 440 834 without GDM and 14 833 with GDM.
The prevalence of GDM increased significantly from 0.7% in
1998 to 1.2% in 2012. Changes in maternal characteristics
were similar in the group without GDM and the group with
GDM (Table 1). There was a significant increase in maternal
age and maternal BMI at first visit to antenatal care. Being of
non-Nordic descent and being primiparous also became
significantly more common. Smoking decreased significantly
over time and chronic hypertension increased significantly,
although remaining a rare condition. Pregnancy duration
became significantly shorter both in women with GDM and
those without over time (Table 1). During the study period,
the number of births increased significantly per year for both
women with GDM (1.047, 95% CI 1.03 to 1.058) and the
background population (1.021, 95% CI 1.018 to 1.024)
(Fig. S1). For both women with and those without GDM,
there was a significant declining trend per year for birth-
weight z-score (GDM: 0.012, 95% CI 0.017 to 0.007;
no GDM: 0.006, 95% CI 0.006 to 0.005) (Fig. S2),
LGA incidence (GDM: 0.986, 95% CI 0.975 to 0.996; no
GDM: 0.987, 95% CI 0.983 to 0.992) (Table 2; Fig. 1) and
birth trauma (GDM: 0.937, 95% CI 0.907 to 0.968; no
GDM: 0.937, 95% CI 0.933 to 0.942) (Table 2; Fig. 2).
However, there was an increase in absolute numbers with
LGA over time due to the growing total number of
pregnancies. There was an increasing trend in SGA incidence
for both women with GDM and those without (GDM:
1.016, 95% CI 1.002 to 1.029; no GDM: 1.007, 95% CI
1.004 to 1.009) (Table 2, Fig. S3). For women with GDM
there were no significant changes in trends in the incidence of
pre-eclampsia, perinatal mortality and prematurity. For
women without GDM, there was a significant decrease in
incidence of pre-eclampsia (0.994, 95% CI 0.989 to 0.999),
perinatal mortality (0.990, 95% CI 0.982 to 0.998) and
premature birth (0.996, 95% CI 0.994 to 0.998), but an
increase in caesarean section rates (1.024, 95% CI 1.017 to
1.031) (Table 2; Figs S1–S7). There were no significant
reductions in pregnancy complications among women with
GDM, but caesarean rates increased overall and LGA rates
increased significantly among women with GDM from 2008.
The overall rate of insulin-treated GDM was 38%. The
frequency changed from 34% in 1998 to 41.5% in 2012.
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Table S1 shows that the trends were comparable within
strata (BMI, non-Nordic descent, smoking, parity and age of
the women) with no significant interaction tests. Excluding
women with intercurrent disease did not change the trends in
outcomes.
Discussion
In this large, population-based cohort study we show that
there have been improvements in some outcomes for women
with GDM. Birthweight, incidence of LGA and birth trauma
have decreased, but SGA and caesarean section incidence
have increased. The same trends are also seen in the general
population. Pre-eclampsia, perinatal mortality and prematu-
rity did not show a significant change in trend for women
with GDM, but in women without GDM there was a
decrease in pre-eclampsia, prematurity and perinatal mor-
tality.
The strength of the study is that it is nationwide, based on
a validated register with prospectively collected data on
almost all pregnancies in Sweden during the study period
[10]. The study incorporates a long period, which diminishes
the possibility of misinterpreting minor changes in trends.
The large data set allows sub-analyses to further evaluate the
results. Limitations include the higher diagnostic plasma
glucose criteria for GDM in Sweden compared with several
other countries. This would result in the inclusion of some
women in the non-GDM group that have GDM by other
criteria, and probably dilutes the differences between the
groups. However, it includes women with indisputable GDM
by any criteria globally. Although there was no abrupt shift
in incidence with the change of capillary testing method, this
was introduced gradually over several years and any impact
could have been obscured by wider secular changes. Another
drawback is the regional differences in screening methods
and variations in diagnostic criteria across the study popu-








































































































































































































































































































































































































































































































































































































































































































































Table 2 Unadjusted incidence trends per year (1998 to 2012) of






0.986 (0.975–0.996) 0.987 (0.983–0.992)
Small for
gestational age
1.016 (1.002–1.029) 1.007 (1.004–1.009)
Birth trauma 0.937 (0.907–0.968) 0.937 (0.933–0.942)
Pre-eclampsia 1.004 (0.989–1.020) 0.994 (0.989–0.999)
Caesarean section 1.016 (1.008–1.024) 1.024 (1.017–1.031)
Perinatal mortality 1.022 (0.996–1.080) 0.990 (0.982–0.998)
Prematurity 1.004 (0.992–1.016) 0.996 (0.994–0.998)
Incidence change per year with 95% CI estimated by Poisson or
negative binomial regression (see statistics for details).
ª 2020 The Authors.
Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK. 2053
Research article DIABETICMedicine
diagnosed with GDM, but during the study period the
variations were between the regions and no major changes
were undertaken in the regions during this time. Compared
with other Nordic countries, Sweden has the most restrictive
screening for GDM, resulting in a very low prevalence. It
cannot be ruled out that the results could be different if the
prevalence of GDM was higher, resulting in a healthier
background population and possibly a lower rate of
FIGURE 1 Trend in incidence per year for LGA for women with GDM 0.986 (0.975-0.996) and women without GDM 0.987 (0.983-0.992).
FIGURE 2 Trends in incidence per year for birth trauma, in women with and without GDM. GDM 0.937 (0.907-0.968), no GDM 0.937 (0.933-
0.942).
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complications in the group with GDM. Although only 1% of
the population had GDM, and this could have limited our
ability to show a statistical difference over time, these are
data are across the whole of Sweden and hence the overall
numbers are large. We cannot rule out that there have been
minor changes in diagnostic criteria over the period of study.
Possible changes could affect results and in part explain the
decrease in LGA. Another limitation is lack of data on
compliance with offered treatment.
No significant trend in perinatal mortality was seen for
women with treated GDM. In the background population,
there was a significant decrease, although small. This is in
line with the findings of Feig et al. [5], although they also
showed that women with GDM were at less risk of perinatal
death than women without diabetes. Compared with that
study, the Swedish incidence of perinatal mortality was
lower.
Birth trauma decreased by ~ 50% both in the GDM group
and the background population. The decrease in birth
trauma could be due to reduction in fetal size since the
results show a decrease in absolute birthweight but also a
decrease in LGA with an increase in SGA babies. The rate of
caesarean section is increased and this could contribute to
reduced birth trauma [15]. Obstetric education and man-
agement in Sweden has changed over the period of study
with a focus on team-based training for adverse, obstetrical
situations, and this could have an impact on the decreasing
rate of birth trauma [16]. The finding of reduced incidence of
birth trauma is of clinical importance and needs further
analysis.
There is no obvious reason for a decrease in the rate of
LGA babies. However, an unexplained increase in inci-
dence of LGA for women with GDM after 2008, needs to
be recognized. The number of cases are too small to be
able to draw conclusions about trends, but these results
need to be followed up. Decreasing birthweight has
previously been shown from the late 1990s onwards
[17]. A large American study reported decreasing birth-
weight in term singletons and the changes could not be
explained by changes in the pregnant population or
obstetric care [18]. Ovesen et al. [6] also showed a
decreasing trend in birthweight and LGA for women with
GDM but they did not present data for the general
population. Contradictory results are reported in England
and Wales, where there was an increase in birthweight
during the period 1986–2012 [19].
During the studied period, numbers with GDM increased
significantly. There is evidence of a change in diet within the
Swedish population [20]. Johansson et al. [21] showed that
total consumption of fat and unsaturated fat increased
significantly during the study period. At the same time,
carbohydrate intake decreased. A diet with less carbohydrate
could lead to a decreased glycaemic load, with potentially
less circulating glucose passing through the placenta to the
fetus, thereby reducing fetal growth. Szilcz et al. [22,23]
showed a slight increase in physical activity during the
studied period but there are also contradicting results that
physical activity has decreased and will continue to do so.
Although this study focused on changes in obstetric out-
comes, the best way to prevent GDM complications would
be to prevent GDM overall, something that has been largely
difficult to achieve to date [24].
There are well-known risk factors for being born SGA
including smoking [25] and pre-eclampsia [26,27], but the
incidence for both smoking and pre-eclampsia decreased in
all women during the studied years in Sweden. This change
would have predicted a decrease in SGA, which did not
occur. A further risk factor for SGA could be intense insulin
treatment in women with GDM [28]. There have been no
national guidelines on treatment goals for GDM in Sweden
and we had no data on the extent of insulin treatment, or on
specific dietary or other management provided to the women
with GDM. Since the trends in outcomes are similar between
women with and without GDM, this is probably not the
explanation.
Indeed, the trends for fetal size (i.e. birthweight, SGA and
LGA) are similar for both women with and without GDM.
This suggests that improved care focused on women with
GDM does not explain our findings. There have not been any
major changes, except development in ultrasound diagnos-
tics, in general obstetric care during these years in Sweden
that would affect estimation of fetal size and concomitant
possible interventions. Changes seen in trends are probably
more related to factors on a population level, such as diet,
exercise and basic maternal care. There was a one day
difference in mean gestational age in the GDM group; so we
think it unlikely that the general increase in induction rates
have had an impact on the results. However, this needs to
analysed further in future studies.
There have been changes in the composition of the group
of pregnant women when analysing BMI, age, ethnic origin
and smoking habits. Stratification by these factors did not
change our findings in relation to trends in outcomes, which
makes it less likely that our results originate from a change
in composition of the pregnant group.
There have been changes in maternal health care or
antenatal care during the study period. Women entered
pregnancy earlier by the end of the study period, which
provided an opportunity for earlier interventions during
pregnancy, e.g. restricting weight gain, dietary advice, and
advice on physical activity. However, to date, randomized
controlled trials have not suggested that birth outcomes are
influenced by lifestyle interventions [29,30].
When analysing the absolute numbers of cases for pre-
eclampsia, caesarean section, prematurity and LGA it is
evident that although there is a decreasing or insignificant
trend for the outcome, absolute numbers of cases are rising
due to increasing numbers of pregnancies. This means that
the overall burden on public health care is increasing despite
decreasing trends in incidence.
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Conclusion
This study shows that there have been improvements in
fetal outcomes for women with GDM between 1998 and
2012, although the incidence of SGA increased. Because
the improvements are similar to or less than the back-
ground population this is probably not due to better
medical care for women with GDM alone. Inequalities in
obstetrical outcomes between women with and without
GDM have continued unchanged, or even worsened, over
15 years in Sweden. New management strategies, such as
screening, diagnosis and treatment of GDM, may be
required to reduce this gap while we await strategies such
as reducing pre-pregnancy obesity that prevent GDM
development.
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